208 related articles for article (PubMed ID: 18511016)
1. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers.
Chu MC; Cushman M; Solomon R; Lobo RA
Am J Obstet Gynecol; 2008 Nov; 199(5):526.e1-7. PubMed ID: 18511016
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
3. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.
Chu MC; Cosper P; Nakhuda GS; Lobo RA
Fertil Steril; 2006 Dec; 86(6):1669-75. PubMed ID: 17074346
[TBL] [Abstract][Full Text] [Related]
4. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
5. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study.
Fait T; Vrablik M; Zizka Z; Kostirova M
Gynecol Obstet Invest; 2008; 65(1):47-51. PubMed ID: 17713346
[TBL] [Abstract][Full Text] [Related]
6. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
Winkler UH; Krämer R; Kwee B; Schindler AE
Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837
[TBL] [Abstract][Full Text] [Related]
7. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J
Menopause; 2006; 13(5):840-5. PubMed ID: 16894332
[TBL] [Abstract][Full Text] [Related]
8. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
Mueck AO; Genazzani AR; Samsioe G; Vukovic-Wysocki I; Seeger H
Menopause; 2007; 14(6):978-84. PubMed ID: 17595593
[TBL] [Abstract][Full Text] [Related]
9. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response.
Silvestri A; Gebara O; Vitale C; Wajngarten M; Leonardo F; Ramires JA; Fini M; Mercuro G; Rosano GM
Circulation; 2003 Jul; 107(25):3165-9. PubMed ID: 12796135
[TBL] [Abstract][Full Text] [Related]
10. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women.
Martínez C; Basurto L; Zárate A; Saucedo R; Gaminio E; Collazo J
Maturitas; 2005 Jan; 50(1):39-43. PubMed ID: 15590212
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome after menopause and the role of hormones.
Lobo RA
Maturitas; 2008 May; 60(1):10-8. PubMed ID: 18407440
[TBL] [Abstract][Full Text] [Related]
12. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
[TBL] [Abstract][Full Text] [Related]
13. Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study.
Fait T; Vrablik M; Cibula D; Masata J; Hill M; Trnkova B
Neuro Endocrinol Lett; 2006 Oct; 27(5):665-8. PubMed ID: 17159824
[TBL] [Abstract][Full Text] [Related]
14. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables.
Kroon UB; Silfverstolpe G; Tengborn L
Thromb Haemost; 1994 Apr; 71(4):420-3. PubMed ID: 8052956
[TBL] [Abstract][Full Text] [Related]
15. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women.
Basurto L; Saucedo R; Zárate A; Martínez C; Gaminio E; Reyes E; Hernandez M
Gynecol Obstet Invest; 2006; 61(2):61-4. PubMed ID: 16192735
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women.
Callejon DR; Franceschini SA; Montes MB; Toloi MR
Maturitas; 2005; 52(3-4):249-55. PubMed ID: 16257613
[TBL] [Abstract][Full Text] [Related]
17. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
[TBL] [Abstract][Full Text] [Related]
19. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
Eur J Obstet Gynecol Reprod Biol; 2009 Feb; 142(2):139-44. PubMed ID: 19095343
[TBL] [Abstract][Full Text] [Related]
20. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women.
Sumino H; Ichikawa S; Ohyama Y; Takahashi T; Saito Y; Nakamura T; Kanda T; Kurabayashi M
Am J Cardiol; 2005 Jul; 96(1):148-53. PubMed ID: 15979455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
